Mucosis B.V. developed prophylactic vaccines using a novel adjuvant platform that enables a more natural immune response as well as a broad base of protection.
Mucosis’s lead vaccine candidate, SynGEM™, was designed to prevent infections with Respiratory Syncytial Virus (RSV), which affect annualy over 60 million people worldwide. An RSV vaccine does not yet exist.
Portfolio: MedSciences Seed Fund B.V. and MedSciences Capital II B.V.
Current product development stage: programme has stopped.